ABT · News · 20261102N
CGM Coverage and Pricing
ABBOTT LABORATORIES · 2026-11-02 · Importance 26 · Surprise 24 · In source text
Abbott and Dexcom are responding to insurance-coverage and pricing changes as Medicare plans to expand continuous glucose monitor coverage to Type 2 diabetes patients who do not use insulin. Abbott anticipates a slowdown and pricing pressure ahead of the expansion, while Dexcom has not reported the same issues and expects a favorable CMS decision. A pharmacy benefit manager’s formulary change is expected to shift coverage from Dexcom to Abbott for some customers in 2027, affecting competition for covered CGM users.
Key facts
- A pharmacy benefit manager’s significant formulary change will shift coverage from Dexcom to Abbott for some customers in 2027. source
- Abbott anticipates a slowdown and pricing pressures ahead of Medicare’s planned expansion of continuous glucose monitor coverage for Type 2 diabetes patients not on insulin. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | A pharmacy benefit manager’s significant formulary change will shift coverage from Dexcom to Abbott for some customers in 2027. |